<DOC>
	<DOCNO>NCT01121705</DOCNO>
	<brief_summary>The study aim evaluate whether current 24 week length combination treatment appropriate patient HCV genotype 3 infection .</brief_summary>
	<brief_title>Efficacy Study New Therapeutic Schedules Naive Hepatitis C Virus ( HCV ) Patients Infected With Genotype 3 ( HCV-3 )</brief_title>
	<detailed_description>Patients randomize standard length treatment variable duration : 12 week patient undetectable HCVRNA week 4 24 36 week detectable HCV RNA week 4 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Naive HCV patient HCVRNA positive Normal TSH ANA &lt; 1:160 Portal hypertension Renal failure HBsAg HIV Alcohol consumption &gt; 30 g/day Active IV drug use Chronic systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>genotype 3</keyword>
	<keyword>Combination treatment</keyword>
	<keyword>Short treatment</keyword>
</DOC>